Answers are grounded in this paper and cite their sources.
Importance Prostate cancer is the most frequently diagnosed non‐cutaneous malignancy and the second leading cause of cancer‐related mortality among men in the United States of America (USA). Despite long‐term improvements in survival, a geographic disparities in disease burden persist across states, and the contributions of the evaluated modifiable risk factors remain incompletely characterized at the state level. Objective To estimate the state‐level burden of prostate cancer in the United States from 1990 to 2023, including incidence, prevalence, death, years lived with disability (YLDs), and disability‐adjusted life years (DALYs), and compare all estimates between two time points (1990–2011, 2012–2023). We also quantified the population attributable fractions (PAFs) for smoking and alcohol use across all 50 states and the District of Columbia. Design, Setting, and Participants This population‐based descriptive study used data from the Global Burden of Disease (GBD) Study 2023. Prostate cancer cases were identified using International Classification of Diseases, Tenth Revision (ICD‐10) code C61. Analyses were restricted to men aged 60 years or older across all 50 US states and the District of Columbia from 1990 to 2023. We compared estimates for 1990–2011 and 2012–2023, using 2012 (the year of the US Preventive Services Task Force (USPSTF) recommendation against routine prostate‐specific antigen (PSA)‐based screening) as a pre‐specified point for splitting the analysis. Population attributable fractions for smoking and high alcohol use were estimated by integrating population exposure distributions with corresponding relative risks within the GBD framework. Main Outcomes and Measures Incidence, prevalence, deaths, YLDs, and DALYs per 100,000 population with 95% uncertainty intervals (UIs). Population attributable fractions for smoking and high alcohol use. Results Between 1990 and 2023, the national incidence rate declined from 973.33 (95% UI, 802.18–1198.94) to 686.13 (95% UI, 559.67–815.74) per 100,000. Prevalence, mortality, YLDs, and DALYs also declined nationally. Compared with 1990–2011, declines after 2012 were attenuated across nearly all outcomes. In 2023, the highest DALY rates were observed in District of Columbia (3273.53 (95% UI, 2799.39–3815.15) per 100,000), Mississippi (2756.13 (95% UI, 2415.51–3122.52) per 100,000), Louisiana (2663.41 (95% UI, 2296.82–3052.23) per 100,000), and Arkansas (2601.63 (95% UI, 2250.45–2978.71) per 100,000), whereas the lowest rates occurred in New York (1873.50 (95% UI, 1604.50–2130.33) per 100,000) and New Jersey (2042.79 (95% UI, 1748.99–2324.32) per 100,000). Smoking‐attributable DALY fractions declined modestly nationally (5.11% (95% UI, 2.07–9.47) to 4.11% (95% UI, 1.57–8.77)), whereas alcohol‐attributable fractions increased from 1.18% (95% UI, 0.02–5.59) to 1.64% (95% UI, 0.05–5.70); neither trend reached statistical significance. Conclusions and Relevance In this population‐based descriptive study, the burden of prostate cancer declined across the USA between 1990 and 2023, and the declines were significantly slower after 2012. Because of the ecological design, these temporal patterns cannot be attributed to the 2012 US Preventive Services Task Force (USPSTF) recommendation or to any other single factor. Persistent geographic disparities and evolving contributions of the evaluated modifiable risk factors highlight the need for targeted, state‐specific prevention and early detection strategies.
No takes yet. Share an insight, caveat, or question.
Ghajarzadeh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: